Spark Therapeutics Inc (NASDAQ:ONCE) insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the sale, the insider now owns 215,000 shares in the company, valued at approximately $15,333,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Spark Therapeutics Inc (NASDAQ ONCE) traded down $25.66 during midday trading on Monday, hitting $47.72. The stock had a trading volume of 14,756,419 shares, compared to its average volume of 459,408. Spark Therapeutics Inc has a twelve month low of $41.06 and a twelve month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.07) earnings per share. research analysts predict that Spark Therapeutics Inc will post -7.6 EPS for the current year.
A number of institutional investors have recently made changes to their positions in ONCE. BlackRock Inc. boosted its stake in Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after acquiring an additional 213,520 shares during the period. Vanguard Group Inc. boosted its stake in Spark Therapeutics by 5.3% in the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after acquiring an additional 96,803 shares during the period. JPMorgan Chase & Co. boosted its stake in Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares during the period. Janus Henderson Group PLC boosted its stake in Spark Therapeutics by 46.4% in the third quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after acquiring an additional 239,723 shares during the period. Finally, Orbimed Advisors LLC acquired a new position in Spark Therapeutics in the third quarter valued at approximately $38,340,000. 94.94% of the stock is owned by hedge funds and other institutional investors.
ONCE has been the topic of a number of research analyst reports. Jefferies Group reiterated a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a report on Tuesday, October 10th. SunTrust Banks set a $101.00 target price on Spark Therapeutics and gave the company a “buy” rating in a report on Monday, October 16th. BMO Capital Markets reiterated a “buy” rating and issued a $101.00 target price on shares of Spark Therapeutics in a report on Wednesday, November 15th. Cowen reissued a “buy” rating and issued a $95.00 price objective on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Finally, Royal Bank Of Canada cut their price objective on Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 8th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $90.97.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Spark Therapeutics Inc (NASDAQ:ONCE) Insider Sells 5,000 Shares of Stock” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/12/11/spark-therapeutics-inc-once-insider-sells-356600-00-in-stock.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.